The price-to-earnings ratio for Hims & Hers Health Inc (NYSE: HIMS) is 76.33x, which is above its average ratio. Moreover, the 36-month beta value for HIMS is 1.89. Analysts have varying opinions on the stock, with 3 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 1 as “sell.”
The public float for HIMS is 183.36M and currently, short sellers hold a 33.08% of that float. On May 05, 2025, HIMS’s average trading volume was 29.30M shares.
HIMS) stock’s latest price update
Hims & Hers Health Inc (NYSE: HIMS)’s stock price has increased by 12.89 compared to its previous closing price of 36.16. However, the company has seen a 45.32% increase in its stock price over the last five trading sessions. zacks.com reported 2025-05-02 that The continued solid uptake of Hims & Hers offerings and expanding subscriber base are likely to have driven the company’s performance in the first quarter of 2025.
HIMS’s Market Performance
HIMS’s stock has risen by 45.32% in the past week, with a monthly rise of 30.75% and a quarterly rise of 9.50%. The volatility ratio for the week is 12.03% while the volatility levels for the last 30 days are 10.80% for Hims & Hers Health Inc The simple moving average for the past 20 days is 40.02% for HIMS’s stock, with a 51.20% simple moving average for the past 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with TD Cowen repeating the rating for HIMS by listing it as a “Hold.” The predicted price for HIMS in the upcoming period, according to TD Cowen is $30 based on the research report published on April 29, 2025 of the current year 2025.
Morgan Stanley, on the other hand, stated in their research note that they expect to see HIMS reach a price target of $60, previously predicting the price at $42. The rating they have provided for HIMS stocks is “Equal-Weight” according to the report published on February 18th, 2025.
Citigroup gave a rating of “Sell” to HIMS, setting the target price at $25 in the report published on January 10th of the current year.
HIMS Trading at 22.33% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.07% of loss for the given period.
Volatility was left at 10.80%, however, over the last 30 days, the volatility rate increased by 12.03%, as shares surge +45.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.53% lower at present.
During the last 5 trading sessions, HIMS rose by +45.32%, which changed the moving average for the period of 200-days by +76.63% in comparison to the 20-day moving average, which settled at $29.15. In addition, Hims & Hers Health Inc saw 68.82% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Boughton Soleil, who sale 3,236 shares at the price of $30.19 back on Apr 28 ’25. After this action, Boughton Soleil now owns 159,662 shares of Hims & Hers Health Inc, valued at $97,695 using the latest closing price.
Dudum Andrew, the Chief Executive Officer of Hims & Hers Health Inc, sale 50,000 shares at $36.39 during a trade that took place back on Apr 29 ’25, which means that Dudum Andrew is holding 92,103 shares at $1,819,310 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.77 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.09. The total capital return value is set at 0.13. Equity return is now at value 30.71, with 21.62 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 22.13.
Currently, EBITDA for the company is 78.99 million with net debt to EBITDA at -2.65. When we switch over and look at the enterprise to sales, we see a ratio of 5.81. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
To wrap up, the performance of Hims & Hers Health Inc (HIMS) has been better in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
